Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea
Status: ACTIVE_NOT_RECRUITING
Study type: OBSERVATIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Patients who received Palbociclib as first line therapy in MBC setting
Sponsor: Pfizer